 |
88 Diseases |  |
68 Trials |
|
68 Trials |  |
2888 News |  |
| «12...89101112131415161718...3536» |
- Ocrevus (ocrelizumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Emergence of spondyloarthritis following B cell-depleting monoclonal antibody therapy for multiple sclerosis () - May 24, 2022 - Abstract #EULAR2022EULAR_3826;
Background: Anti-CD20 B-cell-depleting therapies, including rituximab and ocrelizumab, have demonstrated their efficacy in patients with relapsing–remitting multiple sclerosis (RRMS)...Among the patients with peripheral SpA, 3 of four had inadequate response to NSAIDs, 2 were treated with methotrexate and 1 with leflunomide. We report a pattern of patients with MS successfully treated with B cell-depleting drug developing axial or peripheral SpA, predominantly HLA-B27 negativity and associated with psoriasis.
- Actemra IV (tocilizumab) / Roche, JW Pharma
AORTIC MANIFESTATIONS IN GIANT CELL ARTERITIS: SINGLE CENTRE 10-YEAR EXPERIENCE () - May 24, 2022 - Abstract #EULAR2022EULAR_3559;
Grade 1 diastolic dysfunction can be age related, so this may be association rather than causation 2,3 . Over half of patients had not undergone echocardiogram evaluation, so there may be a hidden burden of disease.
- Actemra IV (tocilizumab) / Roche, JW Pharma
TOCILIZUMAB FOR GIANT CELL ARTERITIS: BASELINE AND TWELVE MONTH AUDIT DATA FROM THE UK BRISTOL AND BATH MULTIDISCIPLINARY MEETING. () - May 24, 2022 - Abstract #EULAR2022EULAR_3552;
The majority of cases had cranial disease, but almost half had either ocular or large vessel involvement, reflecting a severe spectrum of disease. Cases showed a high burden of glucocorticoid toxicity.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
THE ASSESSMENT OF CLINICAL CHARACTERISTICS OF MALE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS () - May 24, 2022 - Abstract #EULAR2022EULAR_3496;
In the current study, the seropositivity was less than in the literature, which may indicate male patients should be cautiously evaluated. Although renal involvement is not an initial manifestation, it may develop during the follow-up.
- DEPENDENCE OF COMPLICATIONS IN TOTAL HIP AND KNEE ARTHROPLASTY ON THE TREATMENT OF RHEUMATOID ARTHRITIS. () - May 24, 2022 - Abstract #EULAR2022EULAR_3368;
The risk of local complications was 3 or more times higher in group of patients with RA without any treatment. So, arthroplasties of large joints in patients with RA without treatment are often accompanied by a high risk of intra- and postoperative complications.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
COMPARISON OF RITUXIMAB VERSUS LEFLUNOMIDE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE TREATMENT- AN OPEN LABEL, RANDOMISED CONTROLLED TRIAL () - May 24, 2022 - Abstract #EULAR2022EULAR_3363;
LEF can be considered as an add-on option to MTX instead of more expensive biologic agents in MTX refractory RA. Larger studies are needed to confirm this hypothesis.
- CLINICAL SIGNIFICANCE OF GALECTIN-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA). () - May 24, 2022 - Abstract #EULAR2022EULAR_3335;
There were no differences in the level of serum galectin-3 in patients with RA and with the ineffectiveness of basic anti-inflammatory therapy and in the control group. At the same time, the association of this marker with RA activity (according to the SDAI, CDAI indices) does not exclude its role in the development of clinical manifestations of rheumatoid arthritis.
- ASSOCIATION OF THE BIOMARKERS SOLUBLE ST2, GALECTIN-3, N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE, PENTRAXIN WITH MYOCARDIAL DYSFUNCTION DETECTED BY SPECKLE TRACKING ECHOCARDIOGRAPHY IN PATIENTS WITH RHEUMATOID ARTHRITIS PRIOR TO BIOLOGICAL THERAPY () - May 24, 2022 - Abstract #EULAR2022EULAR_3284;
In pts with RA frequently (67%) were detected lower global longitudinal epicardial strain, higher levels of NT-proBNP and lower levels of sST2. In RA pts the sST2 biomarker is better associated with inflammatory activity and myocardial dysfunction.
- COMORBIDITIES ARE MORE IMPORTANT THAN JAK INHIBITORS: VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS () - May 24, 2022 - Abstract #EULAR2022EULAR_3246;
RA patients with multimorbidity may have an increasded risk of VTE. In the management of RA, comorbidities should be taken into account.
- leflunomide / Generic mfg.
IDENTIFICATION OF RED FLAGS FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS () - May 24, 2022 - Abstract #EULAR2022EULAR_3237;
In our cohort the first ILD symptom appeared 7.4 years after RA diagnosis. Clinical variables and radiological abnormalities were identified as highly predictive of ILD diagnosis and may represent red flags for an early diagnosis and referral to pneumologists and radiologists in a multidisciplinary approach.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
EFFECTS OF BIOLOGICAL-DMARDs ON THE SERUM URIC ACID LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS () - May 24, 2022 - Abstract #EULAR2022EULAR_3220;
Our study suggests that TNF inhibitor therapy may affect increased percentage of patients with hyperuricemia. On the other hand, non-TNF inhibitor therapy may not affect increased percentage of patients with hyperuricemia and bDMARD treatment has a mild effect on UA levels in patients with RA.
- CLINICAL SIGNIFICANCE OF SOLUBLE ST2 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA). () - May 24, 2022 - Abstract #EULAR2022EULAR_3190;
After 12 months of effective anti-rheumatic therapy, the level of this marker decreased. The association of this marker with the clinical and laboratory activity of RA suggests its role in the development of rheumatoid inflammation.
- REAL-LIFE DAS28-DEFINED REMISSION IN RHEUMATOID ARTHRITIS – INFLAMMATION CONTROL IS NOT ENOUGH () - May 24, 2022 - Abstract #EULAR2022EULAR_3174;
Although reachable, disease remission seems difficult to attain, despite using advanced therapies. High baseline levels of DAS28 are negative predictors for not attaining remission and switching of therapy due to PNR in real-life.
- ASSOCIATION OF SEROLOGICAL STATUS WITH THE FREQUENCY OF CLINICAL AND RADIOLOGICAL REMISSION IN RHEUMATOID ARTHRITIS () - May 24, 2022 - Abstract #EULAR2022EULAR_3141;
The rate of clinical remission (ratio of early in the structure of the general) doesn’t depend on the serological variant of RA: about two thirds of pts in all analysed groups achieve remission in the first 6 mth of DMARD therapy. ACCP- and RF-titers in the onset of the disease don’t influence on the possibility of achieving clinical and radiological remission.
- methotrexate / Generic mfg., sulfasalazine / Generic mfg., leflunomide / Generic mfg.
DENDRITIC CELLS AS TARGETS OF PATHOGENETIC THERAPY FOR AUTOIMMUNE DISEASES () - May 24, 2022 - Abstract #EULAR2022EULAR_2835;
Reduction in the number of DCs in the context of treatment combined with reduced activity of diseases confirm the role of DCs in the pathogenesis of autoimmune diseases. In addition, probably being a target of pathogenetic therapy, they can serve as a marker of a good clinical response to the therapy.
- methotrexate / Generic mfg., leflunomide / Generic mfg.
ATTITUDES TOWARDS MEDICATIONS AND COMMONLY REPORTED SIDE EFFECTS TO DMARDS IN RHEUMATOID ARTHRITIS PATIENTS ATTENDING A TERTIARY CARE HOSPITAL IN SRI LANKA () - May 24, 2022 - Abstract #EULAR2022EULAR_2692;
This was found to be significantly correlated to duration of disease. Educating patients about their medication and clarifying misconceptions will improve compliance and disease outcomes.
- ||| Tai'ai (telitacicept) / Rongchang Pharma
Enrollment open: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - May 23, 2022
P1, N=75, Recruiting, Sponsor: RemeGen Co., Ltd.
Educating patients about their medication and clarifying misconceptions will improve compliance and disease outcomes. Not yet recruiting --> Recruiting
- |||| leflunomide / Generic mfg.
Clinical: Thanks! I'm curious if patient selection or simple durability of TNFi use explains this or if TNFi truly prevent arthritis. I've seen many people get arthritis after stopping TNFi. NB MTX, leflunomide & even switching mesalamine to SSZ sometimes works for peripheral joints (Twitter) - May 23, 2022
- || methotrexate / Generic mfg., cyclosporin A microemulsion / Generic mfg., leflunomide / Generic mfg.
Retrospective data, Review, Journal: A Systematic Review and Network Meta-Analysis about the Efficacy and Safety of Tripterygium wilfordii Hook F in Rheumatoid Arthritis. (Pubmed Central) - May 21, 2022
Assessment of ACR50 response found that TwHF combined with MTX ranked second in all treatment options after cyclosporine A (CsA) combined with leflunomide (LEF) and TwHF alone, followed by TwHF combined with MTX...Compared with the current csDMARDs for treating RA, the efficacy of TwHF was clear, and TwHF combined with MTX performed well under various endpoints. In the future, large, rigorous, and high-quality RCTs are still needed to confirm the benefits of TwHF therapy on RA.
- Emphysematous Cystitis in a Lung Transplant Recipient with BK Viremia (Hynes Halls C & D: Board No. C286) - May 20, 2022 - Abstract #ATC2022ATC_3309;
Antibiotics, immunosuppression modulation, and glycemic control led to successful recovery. Surgical intervention with cystectomy or debridement may be needed in patients with severe necrotizing EC, bladder perforation, or those refractory to medical management.
- prednisone / Generic mfg., leflunomide / Generic mfg.
Metastatic BK Virus-Associated Urothelial Carcinoma Originating in Renal Allograft (Hynes Halls C & D: Board No. C303) - May 20, 2022 - Abstract #ATC2022ATC_2765;
There are some reports of BK virus-associated carcinomas of the bladder and kidney arising in renal transplant patients, however, this case is unique in arising from the allograft kidney and displaying aggressive behavior with locally advanced disease and distant metastases. Furthermore, animal models have shown BK virus to be oncogenic in renal tissue, and proposed this oncogenic model involves T-Ag protein binding to and thus inactivating RB proteins and TP53.
- leflunomide / Generic mfg.
Leflunomide in Children with BK Polyomavirus Viremia After Kidney Transplant (Hynes Halls C & D: Board No. C149) - May 20, 2022 - Abstract #ATC2022ATC_2091;
Leflunomide was well tolerated. While the response rates appeared high, the time to viral clearance was prolonged and the independent effect of leflunomide may have been confounded by concomitant changes in immunosuppression.
- Simulect (basiliximab) / Novartis
High Incidence of BKPyV DNAemia After Simultaneous Pancreas-Kidney Transplantation (Hynes Room 309) - May 20, 2022 - Abstract #ATC2022ATC_1270;
The burden of BKPyV seems increased in SPK recipients, who receive more intensive immunosuppression. Reduction of immunosuppression was mostly safe and effective also in SPK recipients.
- leflunomide / Generic mfg.
Clinical Relevance of Absolute BK Polyoma Viral Load Kinetics in Patients with Biopsy Proven BK Polyomavirus Associated Nephropathy (Hynes Room 309) - May 20, 2022 - Abstract #ATC2022ATC_1269;
This study provides evidence for the prognostic importance of absolute BK viremia kinetics as a dynamic parameter indicating short-term graft survival independently of other established risk factors. Our findings support serial measurement of absolute BK viremia load changes to early identify patients with persistent viremia levels and consequently higher risk for graft loss.
- ||| cholestyramine / Generic mfg., leflunomide / Generic mfg.
She was speaking about common meds used in SLE. However this is an interesting study conducted by OTIS: The rate of birth defects in leflunomide-exposed pregnancies who underwent cholestyramine washout, was not different compared to non-exposed RA group https://t.co/GJQM6pB1ld (Twitter) - May 19, 2022
- || leflunomide / Generic mfg.
Leflunomide? (Twitter) - May 19, 2022
- | Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (clinicaltrials.gov) - May 19, 2022
P4, N=315, Recruiting, Sponsor: University of Oxford
Our findings support serial measurement of absolute BK viremia load changes to early identify patients with persistent viremia levels and consequently higher risk for graft loss. Trial completion date: Feb 2022 --> Aug 2023 | Trial primary completion date: Feb 2022 --> Aug 2023
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Journal: A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis. (Pubmed Central) - May 17, 2022
Outcomes estimated for azathioprine (HR: 0.59, 95% CI: 0.37-0.94), cyclophosphamide (HR: 0.39, 95% CI: 0.20-0.75), and leflunomide (HR: 0.30, 95% CI: 0.11-0.84) were better than those for mycophenolate mofetil...The rates of serious adverse effects did not differ significantly among interventions. Rituximab appears predominant in maintaining remission in patients with ANCA vasculitis with no cost in adverse events.
- | Observational data, Journal: Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil. (Pubmed Central) - May 14, 2022
Methotrexate had the best cost per response ratio, owing to its lower cost and a slightly lower proportion of persistent patients when compared to leflunomide. Leflunomide had a slightly higher medication persistence than methotrexate, but it was the most expensive drug.
- |||| leflunomide / Generic mfg.
Clinical: #ClinicalPearl Everything old is new again. #PsO RCT with #MTX + #Leflunomide Works, relatively ⬇️cost vs advanced therapies. Sl more ⬆️transaminitis, diarrhea #CCR2022 @RheumNowNews ICYMI presented by A Kavanaugh (Twitter) - May 12, 2022
- | leflunomide / Generic mfg.
Trial completion date, Trial primary completion date: Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy (clinicaltrials.gov) - May 12, 2022
P1/2, N=30, Recruiting, Sponsor: City of Hope Medical Center
Leflunomide had a slightly higher medication persistence than methotrexate, but it was the most expensive drug. Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
- | leflunomide / Generic mfg.
Enrollment change, Trial withdrawal: Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients (clinicaltrials.gov) - May 9, 2022
P=N/A, N=0, Withdrawn, Sponsor: Sadat City University
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023 N=600 --> 0 | Enrolling by invitation --> Withdrawn
- COVID19 vaccination in patients with axial and peripheral spondyloarthritis and psoriatic arthritis: adverse events and impact on disease activity (Poster View 9) - May 6, 2022 - Abstract #EULAR2022EULAR_2668;
Vaccination against COVID19 appears to be safe in this population, with only mild adverse events and low frequency of flare disease. Mild adverse events were associated with less use of methotrexate, younger age and lower BMI.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
B-cell reconstitution is strongly associated with a positive serologic response to the COVID-19 booster vaccine in previously serologically unresponsive rituximab treated rheumatic disease patients (Poster View 9) - May 6, 2022 - Abstract #EULAR2022EULAR_2600;
Presence of detectable B-cells and longer time from last rituximab were associated with the development of SARS-CoV-2 spike protein antibodies following the booster vaccine. These factors should be considered in timing of administration of booster vaccine doses in previously unresponsive rituximab treated patients.
- Stelara (ustekinumab) / J&J
COVID-19 in patients with giant cell arteritis (Poster View 9) - May 6, 2022 - Abstract #EULAR2022EULAR_2591;
A quarter of our GCA patients had severe COVID-19. Low doses of glucocorticoids and treatment with leflunomide were not associated with severe COVID-19 course in our cohort.
- Orencia (abatacept) / BMS, Benlysta (belimumab) / GSK, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Immune responses to mRNA vaccines against SARS-CoV2 in patients with immune-mediated inflammatory rheumatic diseases (Poster View 8) - May 6, 2022 - Abstract #EULAR2022EULAR_2588;
Among commonly used therapies, abatacept and B-cell depleting therapies show deleterious effects, while anticytokines preserved immunogenicity. The effects of cumulative methotrexate and glucocorticoid doses on immunogenicity should be considered.
- methotrexate / Generic mfg., leflunomide / Generic mfg.
Do Immunosuppressive agents affect IGRA tests in patients with Rheumatoid arthritis? (Poster View 8) - May 6, 2022 - Abstract #EULAR2022EULAR_2584;
Physicians should be careful in interpretation of QFT-Plus in patients with rheumatoid arthritis. Further analysis including flow cytometry analysis is required to better identifying cut-offs for immunosuppressive individuals and patients with inflammatory rheumatic diseases.
- prednisone / Generic mfg.
Assessing Treatment Patterns with Disease-Modifying Antirheumatic Drugs and Prednisone for Psoriatic Arthritis by Race/Ethnicity (Poster View 7) - May 6, 2022 - Abstract #EULAR2022EULAR_2445;
We found Hispanic patients with PsA to be more likely to receive prednisone prescriptions than White patients with PsA but did not identify any racial/ethnic differences in prescription patterns for oral or biologic DMARDs for PsA. Greater use of prednisone among Hispanic patients may reflect different diseases trajectories (e.g., more disease flares or greater disease severity) or other factors that affect prescription patterns that require further study.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Factors associated with long-term retention of treatment with golimumab in a large cohort of patients with rheumatic diseases, with up to 8 years of follow-up (Poster View 6) - May 6, 2022 - Abstract #EULAR2022EULAR_2335;
This study provides new information on long-term golimumab effectiveness for the treatment or rheumatic diseases, with retention rates of 71% at year 1, 44% at year 5 and 38% at year 8. The probability of golimumab retention was higher as first biological drug, in patients with PsA or axial SpA and in those treated with methotrexate, and lower in those treated with steroids or with higher disease activity at golimumab initiation.
- Xeljanz (tofacitinib) / Pfizer
Efficacy and safety of tofacitinib versus leflunomide treatment in Takayasu arteritis: a prospective study (Poster View 5) - May 6, 2022 - Abstract #EULAR2022EULAR_2191;
LEF and TOF have comparable treatment effects for patients with TAK. However, TOF is superior to LEF in GCs tapering and safety profile.
- Actemra IV (tocilizumab) / Roche, JW Pharma
Treatment, adverse events and follow up in patients with giant cell arteritis in the ARTESER multicenter study (Poster View 5) - May 6, 2022 - Abstract #EULAR2022EULAR_2190;
The cumulative steroid dose was high as well as the side effects. MTX was the most widely used immunosuppressant and TCZ was prescribed in 10%.
- Disease activity burden for long term rheumatology follow-up patients (Poster View 12) - May 6, 2022 - Abstract #EULAR2022EULAR_2050;
Despite T2T approach, use of combination DMARDs and early use of biologics, majority are inflammatory arthritis. It also shows that even after median follow-up of 6 years, these patients require an average review 3 or more times per year.
- Use of biologic or targeted synthetic disease modifying anti-rheumatic drugs and the risk of lymphoma in rheumatoid arthritis (Poster View 11) - May 6, 2022 - Abstract #EULAR2022EULAR_1937;
The bDMARDs included were tumor necrosis factor inhibitors (TNFi) and non-TNFi biologics such as tocilizumab, rituximab, abatacept, and biosimilars; tsDMARD was tofacitinib... In this large study using the nationwide VA data, we did not observe an association between the use of b/ts DMARDs and an increased risk of lymphoma.
- methotrexate / Generic mfg., leflunomide / Generic mfg.
Incidence, clinical features and outcomes of patients with polymyalgia rheumatica in Slovenia (Poster View 11) - May 6, 2022 - Abstract #EULAR2022EULAR_1929;
(1) With the IR of 46 per 105 adults ≥50 years, PMR is more common as rheumatoid arthritis in Slovenia. (2) A considerable proportion of patients required long-term glucocorticoid treatment, leaving a huge unmet need for safer therapeutic options.
- Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in persons with rheumatoid arthritis (Poster View 11) - May 6, 2022 - Abstract #EULAR2022EULAR_1925;
In this nationwide VA study, we did not observe an association between bDMARD use and the incidence of MM. Of note, the median interval from initiation of a bDMARD to the end of follow-up was approximately 5.8 years, which does not allow for an examination of a possible longer term influence.
- Less than 50% females with chronic rheumatic inflammatory diseases continue a DMARD during pregnancy: a descriptive analysis of the national French social security database (Poster View 11) - May 6, 2022 - Abstract #EULAR2022EULAR_1908;
Overall, less than 50% of women with a CRID who received a DMARD prior to the pregnancy continued to retrieve such treatment during pregnancy, and overall less than 20% were delivered biologics during pregnancy. Whether the withdrawal of DMARDs led to unfavorable maternal and pregnancy outcomes needs to be evaluated.
- Lung involvement in VEXAS syndrome (Poster View 10) - May 6, 2022 - Abstract #EULAR2022EULAR_1879;
Respiratory symptoms occurred in over one half of patients and about 20% had PFT abnormalities. The pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement.
- Cimzia (certolizumab pegol) / Astellas, UCB
UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS. (Poster View 10) - May 6, 2022 - Abstract #EULAR2022EULAR_1852;
Prior to CZP, patients had received: methotrexate (n=38), sulfasalazine (28), azathioprine (14), cyclosporine (10), leflunomide (3), mycophenolate mofetil (4), and cyclophosphamide (1)...The most used biologic was adalimumab (n=48), followed by infliximab (32), golimumab (15), tocilizumab (5), etanercept (7), rituximab (1), anakinra (1) and secukinumab (1)... CZP seems to be effective and safe in the control of uveitis associated to different IMIDs.
- | hydroxychloroquine / Generic mfg., mycophenolate mofetil / Generic mfg., leflunomide / Generic mfg.
Enrollment open, Trial primary completion date: NECESSITY: New Clinical End-points in Patients With Primary Sj (clinicaltrials.gov) - May 6, 2022
P2, N=300, Recruiting, Sponsor: Assistance Publique - H
CZP seems to be effective and safe in the control of uveitis associated to different IMIDs. Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2024 --> Feb 2024
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Maintenance Therapies for Anti-Neutrophil Cytoplasmic Antibody Small-Vessel Vasculitis: A Network Meta-Analysis (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1079;
Compared with mycophenolate mofetil, better outcomes were estimated for azathioprine [HR 0.59 (95% CI 0.37–0.94)], cyclophosphamide [HR 0.39 (95% CI 0.20–0.75)] and leflunomide [HR 0.30 (95% CI 0.11–0.84)]...The rates of serious adverse effects did not differ significantly among interventions. CONCLUSION Rituximab appears predominant in maintaining remission in patients with ANCA-vasculitis with no cost in adverse events.